Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Trump has warned that a wave of executive orders would be signed upon him returning to the White House. He and top aide ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

Study shows diabetes drugs' potential beyond weight loss A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and ...

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...

Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

The unprecedented growth in big tech stocks means the U.S. now dominates global markets. U.S.-listed companies made up more than half of the world’s stock market value in 2024 and 70 per cent of the ...